REGENXBIO Inc. - Common Stock (NQ:RGNX)

7.430 +0.010 (+0.13%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm

February 26, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

February 26, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy ↗

February 26, 2026

Following the comments, shares of both Regenxbio and uniQure traded in the red.

Via Stocktwits

RGNX CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

February 25, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

RGNX Shares Pare Losses As Wall Street Dismisses Gene Therapy Clinical Hold Spurred Selloff As An Overreaction ↗

January 28, 2026

Via Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX

February 24, 2026

From Pomerantz LLP

Via GlobeNewswire

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 24, 2026

From Schall Law

Via GlobeNewswire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

February 23, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

February 20, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

RGNX Stockholder Alert: Robbins LLP Remind Investors of the Class Action Lawsuit Against REGENXBIO, Inc.

February 20, 2026

From Robbins LLP

Via GlobeNewswire

Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy ↗

February 20, 2026

While Sarepta’s gene therapy for the treatment of DMD called Elevidys was approved by the FDA in 2023, Regenxbio is developing its treatment.

Via Stocktwits

Topics Intellectual Property Lawsuit

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 20, 2026

From Schall Law

Via GlobeNewswire

REGENXBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against REGENXBIO Inc. and Encourages Investors to Contact the Firm

February 18, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

February 17, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

February 17, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

REGENXBIO Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – RGNX

February 17, 2026

From DJS Law Group

Via Business Wire

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 16, 2026

From The Schall Law Firm

Via Business Wire

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the REGENXBIO, Inc. Securities Class Action Lawsuit

February 16, 2026

From Robbins LLP

Via Business Wire

Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

February 16, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data

February 16, 2026

The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in...

Via MarketMinute

Biotech Beat Nvidia in 2025. Can It Do It Again? ↗

February 11, 2026

Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?

Via The Motley Fool

Topics Artificial Intelligence

Regenxbio Stock Still Has Over 300% Upside Despite FDA Pushback On Hunter Syndrome Drug: Clear Street ↗

February 09, 2026

Clear Street pointed to strength in RGX-202 data for Duchenne and early results from Sura-Vec in wet AMD.

Via Stocktwits

Why Did RGNX Shares Plummet 19% After-Hours Today? ↗

February 09, 2026

REGENXBIO said on Monday that the U.S. Food and Drug Administration (FDA) denied approval for its gene therapy in treating Hunter syndrome, outlining several reasons for the denial.

Via Stocktwits

Monday's after hours session: top gainers and losers ↗

February 09, 2026

Via Chartmill

RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm

February 03, 2026

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX

February 03, 2026

From Pomerantz LLP

Via GlobeNewswire

Kaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law Violations

January 28, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Kaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law Violations

January 28, 2026

NEW YORK, NY - January 28, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against REGENXBIO Inc. (“REGENXBIO” or the “Company”) (NASDAQ: RGNX).

Via TheNewswire.com

Gapping stocks in Wednesday's session ↗

January 28, 2026

Via Chartmill

RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy? ↗

January 28, 2026

REGENXBIO stated that the FDA has placed a clinical hold on the company’s experimental gene therapy program for the treatment of rare childhood diseases.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.